Secukinumab for moderate-to-severe hidradenitis suppurativa
Real-World Evaluation of Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa
This study tests whether secukinumab helps adults with moderate-to-severe hidradenitis suppurativa who have not improved with antibiotics, isotretinoin, or TNF inhibitors.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Peking Union Medical College Academic / other |
| Drugs / interventions | Secukinumab |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT07109765 on ClinicalTrials.gov |
What this trial studies
This is a single-center, prospective observational study conducted at Peking Union Medical College Hospital that gave secukinumab to adults with Hurley stage II or III hidradenitis suppurativa. Participants had disease for at least six months with at least one draining tunnel or two inflammatory nodules and had inadequate responses to prior treatments. Patients were followed for efficacy and safety outcomes, with clinical assessments and ultrasound used to document lesion changes. The study ran from June 1, 2025, to June 1, 2026, under institutional ethics approval and informed consent procedures.
Who should consider this trial
Good fit: Adults aged 18 or older with moderate-to-severe HS (Hurley II–III), disease duration ≥6 months with at least one draining tunnel or two inflammatory nodules, and prior inadequate response to antibiotics, isotretinoin, or TNF inhibitors are ideal candidates.
Not a fit: Patients with mild HS, active infections, recent use of other biologics or systemic immunosuppressants, severe organ dysfunction, or other conditions affecting results are unlikely to benefit or be eligible.
Why it matters
Potential benefit: If successful, secukinumab could reduce inflammatory lesions and improve quality of life for patients with moderate-to-severe HS who have not responded to other therapies.
How similar studies have performed: Other clinical studies of secukinumab in HS have been performed and have shown benefit in some patient subsets, though results across studies have been mixed.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age ≥18 years * diagnosis of moderate-to-severe HS with Hurley stage II or III * Disease duration of ≥6 months, presence of at least one draining tunnel or two inflammatory nodules * inadequate response to prior treatments, such as antibiotics, isotretinoin, or TNF inhibitors Exclusion Criteria: * active infections (e.g., viral hepatitis, active tuberculosis) * use of other biologics or systemic immunosuppressants within the past three months * severe organ dysfunction (e.g., hepatic or renal failure) * any other conditions that might affect study results
Where this trial is running
Beijing, Beijing Municipality
- No. 1 Shuai Fu Yuan, Dongcheng District, Beijing — Beijing, Beijing Municipality, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.